Cargando…
Who may benefit from lower dosages of intravenous tissue plasminogen activator? Results from a cluster data analysis
BACKGROUND: The risk of symptomatic intracranial haemorrhage (sICH) after thrombolysis is low but severe. Lower dose of alteplase may reduce the risk of sICH. We aim to identify subsets of patients who could benefit from lower dose of alteplase compared with standard dose. METHODS: Data from two obse...
Autores principales: | Dong, Yi, Han, Ye, Shen, Haipeng, Wang, Yilong, Ma, Frank, Li, Hao, Wang, Yongjun, Dong, Qiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804063/ https://www.ncbi.nlm.nih.gov/pubmed/32611728 http://dx.doi.org/10.1136/svn-2020-000388 |
Ejemplares similares
-
Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke: an updated systematic review
por: Wang, Xia, et al.
Publicado: (2018) -
GRP per capita and hospital characteristics associated with intravenous tissue plasminogen activator adherence rate: evidence from the Chinese Stroke Center Alliance
por: Zheng, Suxi, et al.
Publicado: (2021) -
Benefit and risk of early intravenous heparin after thrombolysis in patients with acute ischemic stroke
por: Tong, Xu, et al.
Publicado: (2020) -
The Dosage of Intravenous Mercurochrome
por: Elliot, H. L.
Publicado: (1932) -
Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)